176 related articles for article (PubMed ID: 35667143)
21.
Qureshi KA; Azam F; Fatmi MQ; Imtiaz M; Prajapati DK; Rai PK; Jaremko M; Emwas AH; Elhassan GO
PeerJ; 2023; 11():e14502. PubMed ID: 36935926
[TBL] [Abstract][Full Text] [Related]
22. Development of novel monoamine oxidase B (MAO-B) inhibitors by combined application of docking-based alignment, 3D-QSAR, ADMET prediction, molecular dynamics simulation, and MM_GBSA binding free energy.
El Aissouq A; Chedadi O; Bouachrine M; Ouammou A; Khalil F
J Biomol Struct Dyn; 2023 Jul; 41(10):4667-4680. PubMed ID: 35510607
[TBL] [Abstract][Full Text] [Related]
23. Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches.
Dash S; Rathi E; Kumar A; Chawla K; Kini SG
Sci Rep; 2024 May; 14(1):11315. PubMed ID: 38760437
[TBL] [Abstract][Full Text] [Related]
24. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
25. Comparative modeling and dynamic simulation of UDP-N-acetylmuramoyl-alanine ligase (MurC) from Mycobacterium tuberculosis through virtual screening and toxicity analysis.
Isa MA
Life Sci; 2020 Dec; 262():118466. PubMed ID: 32961233
[TBL] [Abstract][Full Text] [Related]
26. Molecular Modeling Studies of
Ghosh S; Keretsu S; Cho SJ
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830393
[TBL] [Abstract][Full Text] [Related]
27. Profiling the interaction mechanism of quinoline/quinazoline derivatives as MCHR1 antagonists: an in silico method.
Wu M; Li Y; Fu X; Wang J; Zhang S; Yang L
Int J Mol Sci; 2014 Sep; 15(9):15475-502. PubMed ID: 25257526
[TBL] [Abstract][Full Text] [Related]
28. Natural products from Brazilian biodiversity identified as potential inhibitors of PknA and PknB of M. tuberculosis using molecular modeling tools.
Antunes SS; Won-Held Rabelo V; Romeiro NC
Comput Biol Med; 2021 Sep; 136():104694. PubMed ID: 34365277
[TBL] [Abstract][Full Text] [Related]
29. Key Structures and Interactions for Binding of Mycobacterium tuberculosis Protein Kinase B Inhibitors from Molecular Dynamics Simulation.
Punkvang A; Kamsri P; Saparpakorn P; Hannongbua S; Wolschann P; Irle S; Pungpo P
Chem Biol Drug Des; 2015 Jul; 86(1):91-101. PubMed ID: 25354564
[TBL] [Abstract][Full Text] [Related]
30. 3D-QSAR, docking and molecular dynamics simulations of novel Pyrazolo-pyridazinone derivatives as covalent inhibitors of FGFR1: a scientific approach for possible anticancer agents.
Hamza S; Abid A; Khanum A; Chohan TA; Saleem H; Maqbool Khan K; Khurshid U; Butt J; Anwar S; Alafnan A; Ansari SA; Qayyum A; Raza A; Chohan TA
J Biomol Struct Dyn; 2024 Mar; 42(5):2242-2256. PubMed ID: 37211823
[TBL] [Abstract][Full Text] [Related]
31. CoMFA, CoMSIA, Topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of breast cancer.
Chhatbar DM; Chaube UJ; Vyas VK; Bhatt HG
Comput Biol Chem; 2019 Jun; 80():351-363. PubMed ID: 31085426
[TBL] [Abstract][Full Text] [Related]
32. In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors.
Asadollahi-Baboli M
Mol Divers; 2016 Aug; 20(3):729-39. PubMed ID: 27209475
[TBL] [Abstract][Full Text] [Related]
33. CoMFA, CoMSIA and HQSAR Analysis of 3-aryl-3-ethoxypropanoic Acid Derivatives as GPR40 Modulators.
Gajjar KA; Gajjar AK
Curr Drug Discov Technol; 2020; 17(1):100-118. PubMed ID: 30160214
[TBL] [Abstract][Full Text] [Related]
34. Probing the Highly Disparate Dual Inhibitory Mechanisms of Novel Quinazoline Derivatives against
Olotu FA; Soliman ME
Molecules; 2020 Sep; 25(18):. PubMed ID: 32947886
[No Abstract] [Full Text] [Related]
35. Identification of the structural features of quinazoline derivatives as EGFR inhibitors using 3D-QSAR modeling, molecular docking, molecular dynamics simulations and free energy calculations.
Wang F; Yang W; Liu H; Zhou B
J Biomol Struct Dyn; 2022; 40(21):11125-11140. PubMed ID: 34338597
[TBL] [Abstract][Full Text] [Related]
36. Design of 2-Nitroimidazooxazine Derivatives as Deazaflavin-Dependent Nitroreductase (Ddn) Activators as Anti-Mycobacterial Agents Based on 3D QSAR, HQSAR, and Docking Study with In Silico Prediction of Activity and Toxicity.
Gupta N; Vyas VK; Patel BD; Ghate M
Interdiscip Sci; 2019 Jun; 11(2):191-205. PubMed ID: 28895050
[TBL] [Abstract][Full Text] [Related]
37. Design of novel dopamine D
Zhang C; Li Q; Meng L; Ren Y
J Biomol Struct Dyn; 2020 Feb; 38(3):860-885. PubMed ID: 30916624
[TBL] [Abstract][Full Text] [Related]
38. 3D-QSAR studies and shape based virtual screening for identification of novel hits to inhibit MbtA in Mycobacterium tuberculosis.
Maganti L; ; Ghoshal N
J Biomol Struct Dyn; 2015; 33(2):344-64. PubMed ID: 24417439
[TBL] [Abstract][Full Text] [Related]
39. An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis.
Agarwal S; Verma E; Kumar V; Lall N; Sau S; Iyer AK; Kashaw SK
J Mol Graph Model; 2018 Aug; 83():17-32. PubMed ID: 29753941
[TBL] [Abstract][Full Text] [Related]
40. Structural insights of PA-824 derivatives: ligand-based 3D-QSAR study and design of novel PA824 derivatives as anti-tubercular agents.
Inturi B; Pujar GV; Purohit MN
J Recept Signal Transduct Res; 2015; 35(5):468-78. PubMed ID: 26053507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
